IMMP News and Press, Immutep Limited From 10/20/25

Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft tissue sarcoma (p<0.001) High level of tumour hyalinization/fibrosis, achieved across multiple STS subtypes, over 3-fold greater than historical r...

Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License Applications (BLA) Registrational TACTI-004 (KEYNOTE-F91) Phase III trial in first line non-small cell lung cancer now in process of opening clinical si...

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysis Over 100 clinical sites across 24 countries now activated and open for recruitment Futility analysis remain...

GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients Second investigator-initiated trial to evaluate efti in earlier stage disease where its unique activation...

2025-09-12 11:44:56 ET ... Read the full article on Seeking Alpha For further details see: Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immu...

Aesthetic Medical International Holdings Group Ltd. (PAIYY) is expected to report for quarter end 2025-06-30 Andina Copper Corporation. (PMMCF) is expected to report for quarter end 2025-06-30 Fathom Nickel (FNICF) is expected to report for quarter end 2025-06-30 Lotus Technology Inc....

Immutep Limited (IMMP) is expected to report for Q4 2025

SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive fe...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countries Trial-in-Progress poster for TACTI-004 presented at the 2025 Ameri...